Literature DB >> 2007580

Aberrant O-linked oligosaccharide biosynthesis in lymphocytes and platelets from patients with the Wiskott-Aldrich syndrome.

E A Higgins1, K A Siminovitch, D L Zhuang, I Brockhausen, J W Dennis.   

Abstract

The Wiskott-Aldrich syndrome (WAS) is an X-linked recessive immunodeficiency affecting B lymphocytes, T lymphocytes, and platelets. Previous studies on lymphocytes from WAS patients have revealed that leu-kosialin (CD43), a cell-surface glycoprotein bearing approximately 90 O-linked oligosaccharide chains, shows an aberrant electrophoretic mobility. To determine whether this finding reflects a different pattern of O-linked glycosylation in WAS cells, we have compared healthy individuals and WAS patients with respect to glycosyltransferase activities in T lymphocytes, platelets, and Epstein-Barr virus (EBV)-immortalized B cell lines. Stimulation of peripheral T cells from normal individuals in vitro with anti-CD3 antibodies and interleukin-2 was associated with a 3-fold increase in UDP-GlcNAc:Gal beta 3GalNAc-R (GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase (core 2 GlcNAc-T) from 0.8 to 2.2 nmol/mg/h. In contrast, peripheral T lymphocytes from WAS patients showed an inversion of this phenotype with high core 2 GlcNAc-T activity in unstimulated cells (2.3 nmol/mg/h) and a 2-3-fold decrease in activity following stimulation. Core 2 GlcNAc-T activity was also three times higher in platelets from WAS patients than in normal platelets. Glycosyltransferase activities were measured in immortalized B cell lines established from WAS and normal subjects by infection with EBV. Core 2 GlcNAc-T was less than 0.4 nmol/mg/h in WAS EBV-B cell lines compared to 2.4 nmol/mg/h in EBV-B cell lines from healthy individuals, In contrast, CMP-SA:SA alpha 2-3Gal beta 1-3GalNAc-R (where SA represents sialyl (sialic acid to GalNAc) alpha 6-sialyltransferase II activity was 2.0 nmol/mg/h in the WAS EBV-B cell and less than .01 nmol/mg/h in EBV-B cell lines derived from normal subjects. Eleven other glycosyltransferase activities were measured and found to be similar in EBV-B cell lines from WAS and normal individuals. Polylactosamine sequences were much reduced in the O-linked oligosaccharides of CD43 from WAS EBV-B cells consistent with decreased core 2 GlcNAc-T activity and expression of core 1 oligosaccharides in the cells. In conclusion, B cells, T cells, and platelets in WAS patients show abnormal expression of two developmentally regulated glycosyltransferases, consistent with the idea that the WAS immunodeficiency is due to a failure of normal lymphocyte maturation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007580

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Development of monoclonal antibodies against bovine mucin core 2 beta6 N-acetylglucosaminyltransferase.

Authors:  C M Li; N Joshee; K B Adler; P W Cheng
Journal:  Glycoconj J       Date:  1999-09       Impact factor: 2.916

2.  Expression of stable human O-glycan core 2 beta-1,6-N-acetylglucosaminyltransferase in Sf9 insect cells.

Authors:  D Toki; M Sarkar; B Yip; F Reck; D Joziasse; M Fukuda; H Schachter; I Brockhausen
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

3.  Development of IgA nephropathy-like glomerulonephritis associated with Wiskott-Aldrich syndrome protein deficiency.

Authors:  M Shimizu; N P Nikolov; K Ueno; K Ohta; R M Siegel; A Yachie; F Candotti
Journal:  Clin Immunol       Date:  2011-10-19       Impact factor: 3.969

Review 4.  Novel clearance mechanisms of platelets.

Authors:  Renata Grozovsky; Karin M Hoffmeister; Hervé Falet
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

Review 5.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

6.  Clinical validation of a link between TNF-alpha and the glycosylation enzyme core 2 GlcNAc-T and the relationship of this link to diabetic retinopathy.

Authors:  B M Ben-Mahmud; W H Chan; R M Abdulahad; A Datti; A Orlacchio; E M Kohner; R Chibber
Journal:  Diabetologia       Date:  2006-07-11       Impact factor: 10.122

7.  Signaling through CD43 regulates CD4 T-cell trafficking.

Authors:  Purvi D Mody; Judy L Cannon; Hozefa S Bandukwala; Kelly M Blaine; Alexander B Schilling; Kevin Swier; Anne I Sperling
Journal:  Blood       Date:  2007-07-16       Impact factor: 22.113

8.  A beta-1,3-N-acetylglucosaminyltransferase with poly-N-acetyllactosamine synthase activity is structurally related to beta-1,3-galactosyltransferases.

Authors:  D Zhou; A Dinter; R Gutiérrez Gallego; J P Kamerling; J F Vliegenthart; E G Berger; T Hennet
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

9.  Processing O-glycan core 1, Gal beta 1-3GalNAc alpha-R. Specificities of core 2, UDP-GlcNAc: Gal beta 1-3 GalNAc-R(GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase and CMP-sialic acid: Gal beta 1-3GalNAc-R alpha 3-sialyltransferase.

Authors:  W Kuhns; V Rutz; H Paulsen; K L Matta; M A Baker; M Barner; M Granovsky; I Brockhausen
Journal:  Glycoconj J       Date:  1993-10       Impact factor: 2.916

10.  Studies of the expression of the Wiskott-Aldrich syndrome protein.

Authors:  D M Stewart; S Treiber-Held; C C Kurman; F Facchetti; L D Notarangelo; D L Nelson
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.